Literature DB >> 1969875

The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity.

M Hegen1, G Niedobitek, C E Klein, H Stein, B Fleischer.   

Abstract

Tp103 is a 103-kDa T cell activation molecule that defines an alternative activation signal for human T lymphocytes. It is absent from or present in only low amounts on resting T cells but is expressed strongly after activation. Cross-linking of Tp103 via a mAb CB.1 leads to triggering of functional activities in preactivated CD3+ T lymphocytes. By using mAb CB.1 in immunohistology we found that Tp103 is expressed in epithelial cells of various tissues, such as kidney, prostate, epidermis and on endothelia of liver, spleen, lungs, and most vessels, and in bile duct canaliculi in the liver. We found a carcinoma cell line expressing Tp103 and could precipitate a 110-kDa molecule from the surface of these cells. We considered several known molecules of similar distribution and molecular mass for identity with Tp103 and show here that Tp103 is probably identical to the proteolytic enzyme dipeptidyl aminopeptidase IV. When we purified Tp103 by affinity chromatography, typical dipeptidyl aminopeptidase IV activity copurified with Tp103. On activated T cells the enzymatic activity associated with Tp103 is expressed on the outside of the cell. We show that mAb CB.1 recognizes the same molecule as the anti-CD26 mAb anti-Ta1. The anti-Ta1 mAb was found to have T cell-activating activity too, but to differ in its requirements for triggering of T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969875

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Different effects of steroidal therapy on neuropeptide-active enzymes in male and female human saliva.

Authors:  Federica Albo; Riccardo Antonangeli; Antonella Cavazza; Mario Marini; L Giorgio Roda; Paolo Rossi
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

2.  Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family.

Authors:  K Wada; N Yokotani; C Hunter; K Doi; R J Wenthold; S Shimasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

Authors:  T Yamabe; K Takakura; K Sugie; Y Kitaoka; S Takeda; Y Okubo; K Teshigawara; J Yodoi; T Hori
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

4.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 5.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

6.  CD26 induces T-cell proliferation by tyrosine protein phosphorylation.

Authors:  E Muñoz; M V Blazquez; J A Madueño; G Rubio; J Peña
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

7.  Involvement of dipeptidyl peptidase IV in an in vivo immune response.

Authors:  T Kubota; G R Flentke; W W Bachovchin; B D Stollar
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 8.  The evolution of proteinase substrates with special reference to dipeptidylpeptidase IV.

Authors:  R E Smith; C J Reynolds; E A Elder
Journal:  Histochem J       Date:  1992-09

9.  Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.

Authors:  M W Carr; S J Roth; E Luther; S S Rose; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

Authors:  J M Bathon; D Proud; S Mizutani; P E Ward
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.